Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100B | P04271 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655093 | 0.91 | S100B (0.52) | S100BCYP3A4TSHRMAPK1ALDH1A1 | |
| Thiourea SCHEMBL650897 | 0.91 | S100B (0.44) | S100BCYP3A4TSHRMAPK1ALDH1A1 | |
| Thiourea SCHEMBL651375 | 0.83 | S100B (0.44) | S100BCYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL8960786 | 0.82 | S100B (0.47) | S100BCYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL19121257 | 0.81 | S100B (0.39) | S100BCYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL23964505 | 0.79 | CYP3A4 (0.44) | S100BCYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL11431479 | 0.79 | S100B (0.44) | S100BCYP3A4ALDH1A1L3MBTL1GFER | |
| SCHEMBL11034293 | 0.78 | S100B (0.47) | S100BCYP3A4TSHRMAPK1ALDH1A1 | |
| SCHEMBL11259510 | 0.76 | TP53 (0.43) | S100BALDH1A1ALOX15HSD17B10TDP1 | |
| SCHEMBL21208575 | 0.76 | S1PR1 (0.38) | S100BALDH1A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021162115-A1 | LAMINATE, DISPLAY DEVICE, AND ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE | 富士フイルム株式会社 | 2021-08-19 | — | — | WO | disclosed |
| WO-2021132674-A1 | LIGHT ABSORBING FILTER, OPTICAL FILTER, ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE | 富士フイルム株式会社 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021014973-A1 | WAVELENGTH-SELECTIVE ABSORPTION FILTER AND ORGANIC ELECTROLUMINESCENCE DISPLAY DEVICE | 富士フイルム株式会社 | 2021-01-28 | — | — | WO | disclosed |
| WO-2020116642-A1 | RESIN COMPOSITION, OPTICAL FILTER, IMAGE DISPLAY DEVICE, SOLID-STATE IMAGING ELEMENT, AND DYE MIXTURE | 富士フイルム株式会社 | 2020-06-11 | — | — | WO | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1628666-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | Torreypines Therapeutics, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | SIROCCO THERAPEUTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-4233399-A | Photographic elements containing amino-substituted hydroxy-pyridones | CIBA-GEIGY AKTIENGESELLSCHAFT (CH) | 1980-11-11 | — | — | US | disclosed |
| US-4182886-A | OPTICAL FILTERS IN COLOR PHOTOGRAPHY | CIBA-GEIGY AKTIENGESELLSCHAFT (CH) | 1980-01-08 | — | — | US | disclosed |
| US-3974041-A | Image recording member with zeolitic water containing compounds | CANON KABUSHIKI KAISHA (JA) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | APP, BACE1, BACE2 | S100B 32/4885CYP3A4 4119/4885TSHR 4723/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | S100B 212/4885CYP3A4 3951/4885TSHR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.